Ascendis Pharma A (ASND) Tax Provisions (2014 - 2026)

Ascendis Pharma A (ASND) has 13 years of Tax Provisions data on file, last reported at -$793.2 million in Q1 2026.

• For the quarter ending Q1 2026, Tax Provisions fell 70972.03% year-over-year to -$793.2 million; the trailing twelve-month figure through Mar 2026 stood at -$809.8 million (down 22132.45% YoY), and the FY2025 full-year result was $46.2 million, up 781.44% from the prior year.
• Tax Provisions retreated to -$793.2 million in Q1 2026, from -$8.0 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $467148.6 in Q2 2023 to a low of -$793.2 million in Q1 2026.
• A 5-year average of -$48.8 million and a median of -$1.2 million in 2024 frame the typical range for Tax Provisions.
• Across the five-year window, Tax Provisions soared 2279.71% in 2022 and sank 70972.03% in 2026, its largest moves.
• Tracing ASND's Tax Provisions over 5 years: stood at -$5.5 million in 2022, then declined by 14.19% to -$6.2 million in 2023, then jumped by 81.39% to -$1.2 million in 2024, then tumbled by 588.43% to -$8.0 million in 2025, then slumped by 9837.54% to -$793.2 million in 2026.
• Business Quant data shows ASND's Tax Provisions at -$793.2 million in Q1 2026, -$8.0 million in Q4 2025, and -$4.2 million in Q3 2025.